{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:21:50Z","timestamp":1786123310813,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>\n                      Lorazepam is used as premedication for its anxiolytic properties. The\n                      <jats:italic toggle=\"yes\">UGT2B15<\/jats:italic>\n                      genotype is of importance for the metabolism of lorazepam. The clinical effect of genetic polymorphisms in\n                      <jats:italic toggle=\"yes\">UGT2B15<\/jats:italic>\n                      genotype on the treatment of anxiety levels in same-day surgery patients receiving lorazepam, however, is unknown.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>\n                      Three hundred ninety-eight same-day surgery patients of mixed sex (from a previous double-blinded randomized controlled trial who were assigned to either lorazepam [n = 198] or placebo [n = 200]) were assessed for the\n                      <jats:italic toggle=\"yes\">UGT2B15*2<\/jats:italic>\n                      variant allele. Anxiety was measured preoperatively and postoperatively by the State part of the State-Trait Anxiety Inventory. The difference between these 2 measurements served as outcome of the study. Analysis of variance was used to assess the State part of the State-Trait Anxiety Inventory difference for interactions among the following factors:\n                      <jats:italic toggle=\"yes\">UGT2B15<\/jats:italic>\n                      genotype status, treatment condition (lorazepam or placebo), patient sex, and preoperative anxiety score.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      The anxiety difference was complex in that the interaction of lorazepam and\n                      <jats:italic toggle=\"yes\">UGT2B15<\/jats:italic>\n                      genotype status also was dependent on the joint effect of patient sex and preoperative anxiety score (F = 7.15,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .008). Further exploration showed clinical relevant results in patients with high preoperative anxiety scores. Striking was that females with high preoperative anxiety scores and genetically reduced lorazepam glucuronidation (\n                      <jats:italic toggle=\"yes\">UGT2B15*2<\/jats:italic>\n                      homozygotes) showed more postoperative anxiety reduction than males with the same genotype.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">UGT2B15<\/jats:italic>\n                      genotype contributes to postoperative anxiety reduction after lorazepam premedication. Future research that focuses on patients with high preoperative anxiety scores could help to gain a deeper understanding in the clinical relevance of the interaction between lorazepam and\n                      <jats:italic toggle=\"yes\">UGT2B15<\/jats:italic>\n                      genotype on postoperative anxiety levels.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1213\/ane.0000000000001508","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T06:22:57Z","timestamp":1473747777000},"page":"1109-1115","source":"Crossref","is-referenced-by-count":8,"title":["Implication of UGT2B15 Genotype Polymorphism on Postoperative Anxiety Levels in Patients Receiving Lorazepam Premedication"],"prefix":"10.1213","volume":"123","author":[{"given":"Herjan","family":"Mijderwijk","sequence":"first","affiliation":[{"name":"Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Klimek","sequence":"additional","affiliation":[{"name":"Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"van Beek","sequence":"additional","affiliation":[{"name":"Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. N.","family":"van Schaik","sequence":"additional","affiliation":[{"name":"Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo J.","family":"Duivenvoorden","sequence":"additional","affiliation":[{"name":"Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Jan","family":"Stolker","sequence":"additional","affiliation":[{"name":"Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230812","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00003088-199936060-00005","article-title":"Glucuronidation in humans. Pharmacogenetic and developmental aspects.","volume":"36","author":"de Wildt","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"R2-20230812","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","article-title":"The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification.","volume":"45","author":"Rowland","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"R3-20230812","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev.pharmtox.40.1.581","article-title":"Human UDP-glucuronosyltransferases: metabolism, expression, and disease.","volume":"40","author":"Tukey","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R4-20230812","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2165\/00003495-198121030-00001","article-title":"Lorazepam: a review of its clinical pharmacological properties and therapeutic uses.","volume":"21","author":"Ameer","year":"1981","journal-title":"Drugs"},{"key":"R5-20230812","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2005.02.006","article-title":"Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers.","volume":"77","author":"Chung","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R6-20230812","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00008571-199708000-00007","article-title":"Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene.","volume":"7","author":"L\u00e9vesque","year":"1997","journal-title":"Pharmacogenetics"},{"key":"R7-20230812","doi-asserted-by":"crossref","first-page":"12617","DOI":"10.1523\/JNEUROSCI.2696-09.2009","article-title":"Effects of Lorazepam and citalopram on human defensive reactions: ethopharmacological differentiation of fear and anxiety.","volume":"29","author":"Perkins","year":"2009","journal-title":"J Neurosci"},{"key":"R8-20230812","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-3-540-74806-9_16","article-title":"Midazolam and other benzodiazepines.","author":"Olkkola","year":"2008","journal-title":"Handb Exp Pharmacol"},{"key":"R9-20230812","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/EJA.0b013e328361d395","article-title":"Lorazepam does not improve the quality of recovery in day-case surgery patients: a randomised placebo-controlled clinical trial.","volume":"30","author":"Mijderwijk","year":"2013","journal-title":"Eur J Anaesthesiol"},{"key":"R10-20230812","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/0269881105056659","article-title":"Gender differences in response to lorazepam in a human drug discrimination study.","volume":"19","author":"Jackson","year":"2005","journal-title":"J Psychopharmacol"},{"key":"R11-20230812","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0022-3565(25)21328-3","article-title":"Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam.","volume":"250","author":"Greenblatt","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"R13-20230812","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2125.2009.03519.x","article-title":"Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion.","volume":"68","author":"He","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R14-20230812","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/001316447403400406","article-title":"An empirical comparison of the ANOVA F-test, normal scores test and Kruskal-Wallis test under violation of assumptions.","volume":"34","author":"Feir-Walsh","year":"1974","journal-title":"Educ Psychol Meas."},{"key":"R15-20230812","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1027\/1614-2241\/a000016","article-title":"Is it really robust?","volume":"6","author":"Schmider","year":"2010","journal-title":"Methodology"},{"key":"R16-20230812","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.neuroscience.2014.11.053","article-title":"The effects of morphine, naloxone, and \u03ba opioid manipulation on endocrine functioning and social behavior in monogamous titi monkeys (Callicebus cupreus).","volume":"287","author":"Ragen","year":"2015","journal-title":"Neuroscience"},{"key":"R17-20230812","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bbr.2015.02.033","article-title":"Cardioacceleration in alloparents in response to stimuli from prairie vole pups: the significance of thermoregulation.","volume":"286","author":"Kenkel","year":"2015","journal-title":"Behav Brain Res"},{"key":"R20-20230812","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1213\/01.ANE.0000181331.59738.66","article-title":"The legend of the P value.","volume":"101","author":"Kain","year":"2005","journal-title":"Anesth Analg"},{"key":"R21-20230812","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.psyneuen.2004.02.003","article-title":"Effects of PhD examination stress on allopregnanolone and cortisol plasma levels and peripheral benzodiazepine receptor density.","volume":"29","author":"Droogleever Fortuyn","year":"2004","journal-title":"Psychoneuroendocrinology"},{"key":"R22-20230812","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0165-0173(01)00111-4","article-title":"Brain androgen and progesterone metabolizing enzymes: biosynthesis, distribution and function.","volume":"37","author":"Lephart","year":"2001","journal-title":"Brain Res Brain Res Rev"},{"key":"R23-20230812","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0165-0173(01)00124-2","article-title":"Modulation of native and recombinant GABA(A) receptors by endogenous and synthetic neuroactive steroids.","volume":"37","author":"Lambert","year":"2001","journal-title":"Brain Res Brain Res Rev"},{"key":"R24-20230812","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pneurobio.2003.09.001","article-title":"Neurosteroid modulation of GABAA receptors.","volume":"71","author":"Lambert","year":"2003","journal-title":"Prog Neurobiol"},{"key":"R25-20230812","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0306-4530(02)00064-1","article-title":"Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties.","volume":"28","author":"Rupprecht","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"R26-20230812","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1046\/j.1365-2044.2003.03295_5.x","article-title":"Towards needleless induction of anaesthesia.","volume":"58","author":"van den Berg","year":"2003","journal-title":"Anaesthesia"},{"key":"R27-20230812","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2015.1108","article-title":"Effect of sedative premedication on patient experience after general anesthesia: a randomized clinical trial.","volume":"313","author":"Maurice-Szamburski","year":"2015","journal-title":"JAMA"},{"key":"R28-20230812","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2710.2000.00281.x","article-title":"Pharmacogenetics and psychopharmacotherapy.","volume":"25","author":"Poolsup","year":"2000","journal-title":"J Clin Pharm Ther"},{"key":"R29-20230812","first-page":"329","article-title":"Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y).","volume":"9","author":"Lampe","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R30-20230812","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00228-012-1382-7","article-title":"The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.","volume":"69","author":"Stringer","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R31-20230812","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/bja\/aeh200","article-title":"Principles of pharmacogenetics\u2014implications for the anaesthetist.","volume":"93","author":"Iohom","year":"2004","journal-title":"Br J Anaesth"},{"key":"R32-20230812","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2044.2011.06918.x","article-title":"Pharmacogenetics and anaesthesia: the value of genetic profiling.","volume":"67","author":"Landau","year":"2012","journal-title":"Anaesthesia"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000539-201611000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:21:53Z","timestamp":1786112513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000539-201611000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000001508","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}